Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
2.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
3.

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D.

J Clin Oncol. 2018 Aug 20;36(24):2545-2556. doi: 10.1200/JCO.2018.78.9636. Epub 2018 May 23.

PMID:
29791286
4.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
5.

A Blueprint to Advance Colorectal Cancer Immunotherapies.

Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA Jr, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQ, McAbee K, Worrall S, Benson AB.

Cancer Immunol Res. 2017 Nov;5(11):942-949. doi: 10.1158/2326-6066.CIR-17-0375. Epub 2017 Oct 16.

6.

Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D.

J Natl Compr Canc Netw. 2017 Mar;15(3):370-398.

PMID:
28275037
7.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

8.

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC.

Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.

9.

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP.

J Clin Oncol. 2015 Nov 20;33(33):3874-9.

PMID:
26438119
10.

Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.

Paspulati RM, Partovi S, Herrmann KA, Krishnamurthi S, Delaney CP, Nguyen NC.

Abdom Imaging. 2015 Aug;40(6):1415-25. doi: 10.1007/s00261-015-0474-0.

PMID:
26112492
11.

The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients.

Xu F, Rimm AA, Fu P, Krishnamurthi SS, Cooper GS.

PLoS One. 2014 Sep 19;9(9):e107993. doi: 10.1371/journal.pone.0107993. eCollection 2014.

12.

Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.

Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O'Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell J.

Oncologist. 2013;18(10):1091-2. doi: 10.1634/theoncologist.2013-0255. Epub 2013 Sep 26.

13.

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.

LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S.

Invest New Drugs. 2014 Apr;32(2):303-11. doi: 10.1007/s10637-013-9998-8. Epub 2013 Aug 1.

PMID:
23903897
14.

The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.

El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E.

Cancer Chemother Pharmacol. 2013 Jul;72(1):53-64. doi: 10.1007/s00280-013-2168-z. Epub 2013 May 30.

PMID:
23719718
15.

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.

Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, Chiorean EG.

J Gastrointest Surg. 2013 Jan;17(1):94-100; discussion p. 100-1. doi: 10.1007/s11605-012-2064-6. Epub 2012 Nov 15.

PMID:
23229886
16.

Phase I trial of pomalidomide given for patients with advanced solid tumors.

Cooney MM, Nock C, Bokar J, Krishnamurthi S, Gibbons J, Rodal MB, Ness A, Remick SC, Dreicer R, Dowlati A.

Cancer Chemother Pharmacol. 2012 Nov;70(5):755-61. doi: 10.1007/s00280-012-1919-6. Epub 2012 Aug 9.

PMID:
22875080
17.

Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.

Brell JM, Krishnamurthi SS, Rath L, Bokar JA, Savvides P, Gibbons J, Cooney MM, Meropol NJ, Ivy P, Dowlati A.

Cancer Chemother Pharmacol. 2012 Oct;70(4):547-53. Epub 2012 Aug 7.

18.

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.

Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA.

Clin Cancer Res. 2012 Feb 15;18(4):1092-100. doi: 10.1158/1078-0432.CCR-11-2378. Epub 2011 Dec 16.

19.

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N.

Clin Colorectal Cancer. 2012 Mar;11(1):53-9. doi: 10.1016/j.clcc.2011.05.003. Epub 2011 Aug 2.

PMID:
21813336
20.

Colorectal carcinoma: overview of clinical research and management 2011.

Krishnamurthi SS, Meropol NJ.

Semin Oncol. 2011 Aug;38(4):481-2. doi: 10.1053/j.seminoncol.2011.05.001. No abstract available.

PMID:
21810506
21.

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, DePrimo SE, Bentivegna S, Wilner KD, Tan W, Ricart AD.

Clin Cancer Res. 2010 Mar 15;16(6):1924-37. doi: 10.1158/1078-0432.CCR-09-1883. Epub 2010 Mar 9.

22.

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.

Nock CJ, Brell JM, Bokar JA, Cooney MM, Cooper B, Gibbons J, Krishnamurthi S, Manda S, Savvides P, Remick SC, Ivy P, Dowlati A.

Invest New Drugs. 2011 Feb;29(1):126-30. doi: 10.1007/s10637-009-9322-9. Epub 2009 Sep 23.

23.

Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.

Dowlati A, Posey J, Ramanathan RK, Rath L, Fu P, Chak A, Krishnamurthi S, Brell J, Ingalls S, Hoppel CL, Ivy P, Remick SC.

Cancer Chemother Pharmacol. 2009 Dec;65(1):73-8. doi: 10.1007/s00280-009-1005-x. Epub 2009 Apr 28.

24.

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM.

Invest New Drugs. 2009 Oct;27(5):453-60. doi: 10.1007/s10637-008-9200-x. Epub 2008 Nov 15.

PMID:
19011760
25.

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.

Brell JM, Krishnamurthi SS, Javle M, Saltzman J, Wollner I, Pelley R, Dowlati A, Kantharaj BN, Schluchter MD, Rath L, Ivy SP, Remick SC.

Cancer Chemother Pharmacol. 2009 Apr;63(5):851-7. doi: 10.1007/s00280-008-0807-6. Epub 2008 Aug 1.

26.

Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.

Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC.

Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.

27.

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC.

Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15.

28.

Evaluation and management of incidental thyroid nodules in patients with another primary malignancy.

Wilhelm SM, Robinson AV, Krishnamurthi SS, Reynolds HL.

Surgery. 2007 Oct;142(4):581-6; discussion 586-7.

PMID:
17950351
29.

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.

J Clin Oncol. 2007 Aug 1;25(22):3230-7.

PMID:
17664471
30.

Adjuvant therapy for rectal cancer.

Krishnamurthi SS, Seo Y, Kinsella TJ.

Clin Colon Rectal Surg. 2007 Aug;20(3):167-81. doi: 10.1055/s-2007-984861.

31.

A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.

Mackay HJ, Billingsley K, Gallinger S, Berry S, Smith A, Yeung R, Pond GR, Croitoru M, Swanson PE, Krishnamurthi S, Siu LL.

Am J Clin Oncol. 2005 Dec;28(6):547-54.

PMID:
16317262
32.

ErbB family targeting.

Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK.

Curr Opin Investig Drugs. 2003 Dec;4(12):1451-4. Review.

PMID:
14763131

Supplemental Content

Loading ...
Support Center